Highland Peak Capital LLC Buys 179,114 Shares of Grifols, S.A. (NASDAQ:GRFS)

Highland Peak Capital LLC grew its stake in Grifols, S.A. (NASDAQ:GRFS) by 29.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 786,210 shares of the biotechnology company’s stock after purchasing an additional 179,114 shares during the period. Grifols makes up about 3.2% of Highland Peak Capital LLC’s portfolio, making the stock its 11th biggest position. Highland Peak Capital LLC’s holdings in Grifols were worth $5,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of GRFS. R Squared Ltd bought a new stake in shares of Grifols in the 4th quarter valued at approximately $28,000. GAMMA Investing LLC raised its holdings in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares during the period. Blue Trust Inc. raised its holdings in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,970 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Grifols in the fourth quarter worth approximately $91,000. Finally, HighTower Advisors LLC raised its holdings in shares of Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,546 shares during the period.

Grifols Trading Down 0.8 %

Shares of NASDAQ:GRFS opened at $8.43 on Monday. Grifols, S.A. has a 12-month low of $5.68 and a 12-month high of $9.96. The business’s fifty day simple moving average is $7.47 and its 200-day simple moving average is $8.16. The company has a market capitalization of $5.80 billion, a PE ratio of 7.21 and a beta of 0.35. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley began coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.